{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:33:46Z","timestamp":1762511626825,"version":"build-2065373602"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332018130"],"award-info":[{"award-number":["3332018130"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004384","name":"Instytut Biologii Medycznej Polskiej Akademii Nauk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004384","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.heliyon.2019.e01297","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T06:08:46Z","timestamp":1551938926000},"page":"e01297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic antibodies for mantle cell lymphoma: A\u00a0brand-new era ahead"],"prefix":"10.1016","volume":"5","author":[{"given":"Ming","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2684-512X","authenticated-orcid":false,"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/14712598.2015.1055241","article-title":"Ofatumumab in the treatment of non-Hodgkin's lymphomas","volume":"15","author":"Karlin","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib2","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"38","key":"10.1016\/j.heliyon.2019.e01297_bib3","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1038\/sj.onc.1202997","article-title":"Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector","volume":"18","author":"Adams","year":"1999","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.heliyon.2019.e01297_bib4","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"issue":"45","key":"10.1016\/j.heliyon.2019.e01297_bib5","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.heliyon.2019.e01297_bib6","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1158\/0008-5472.CAN-16-0595","article-title":"TG2 and NF-kappaB signaling coordinates the survival of mantle cell lymphoma cells via IL6-mediated autophagy","volume":"76","author":"Zhang","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood-2017-02-767293","article-title":"Bifurcated BACH2 control coordinates mantle cell lymphoma survival and dispersal during hypoxia","volume":"130","author":"Zhang","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib9","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5013","key":"10.1016\/j.heliyon.2019.e01297_bib10","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1126\/science.2047874","article-title":"Monoclonal antibodies in diagnosis and therapy","volume":"252","author":"Waldmann","year":"1991","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.heliyon.2019.e01297_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","article-title":"Monoclonal antibody-based therapies of leukemia and lymphoma","volume":"80","author":"Grossbard","year":"1992","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.heliyon.2019.e01297_bib12","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2010-04-001230","article-title":"The clinical application of monoclonal antibodies in chronic lymphocytic leukemia","volume":"116","author":"Jaglowski","year":"2010","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.heliyon.2019.e01297_bib13","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2014-08-596403","article-title":"Monoclonal antibodies in acute lymphoblastic leukemia","volume":"125","author":"Jabbour","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.heliyon.2019.e01297_bib14","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies","volume":"128","author":"Hoyos","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib15","first-page":"156","article-title":"Rituximab in diffuse large B-cell lymphoma","volume":"2","author":"Coiffier","year":"2004","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"25","key":"10.1016\/j.heliyon.2019.e01297_bib16","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1038\/sj.onc.1210376","article-title":"Rituximab therapy in malignant lymphoma","volume":"26","author":"Coiffier","year":"2007","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1053\/beha.2002.0222","article-title":"Antibody-based therapy of non-Hodgkin's lymphoma","volume":"15","author":"Foran","year":"2002","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.heliyon.2019.e01297_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2019.e01297_bib21","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib22","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.heliyon.2019.e01297_bib23","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.heliyon.2019.e01297_bib25","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","volume":"377","author":"Le Gouill","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib26","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/cas.13719","article-title":"R-High-CHOP\/CHASER\/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY","volume":"109","author":"Ogura","year":"2018","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in\u00a0vitro and in\u00a0vivo","volume":"35","author":"Qian","year":"2011","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1016\/j.heliyon.2019.e01297_bib29","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib30","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/annonc\/mdw158","article-title":"Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas","volume":"27","author":"Ruan","year":"2016","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2019.e01297_bib31","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","article-title":"Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas","volume":"21","author":"Chong","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br. J. Haematol."},{"issue":"29","key":"10.1016\/j.heliyon.2019.e01297_bib35","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib39","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.heliyon.2019.e01297_bib40","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.heliyon.2019.e01297_bib41","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","article-title":"Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma","volume":"26","author":"Robinson","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib42","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2019.e01297_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-5-64","article-title":"Novel CD20 monoclonal antibodies for lymphoma therapy","volume":"5","author":"Cang","year":"2012","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.heliyon.2019.e01297_bib45","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1158\/1078-0432.CCR-15-0056","article-title":"Ofatumumab exhibits enhanced in\u00a0vitro and in\u00a0vivo activity compared to rituximab in preclinical models of mantle cell lymphoma","volume":"21","author":"Barth","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.heliyon.2019.e01297_bib46","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.12769","article-title":"Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma \u2013 a phase II trial","volume":"165","author":"Furtado","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.heliyon.2019.e01297_bib47","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2012.09086.x","article-title":"Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma","volume":"157","author":"Czuczman","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"19","key":"10.1016\/j.heliyon.2019.e01297_bib48","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2012.45.9438","article-title":"Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma","volume":"31","author":"Hunstig","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ctrv.2015.07.003","article-title":"Obinutuzumab in hematologic malignancies: lessons learned to date","volume":"41","author":"Illidge","year":"2015","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2010-09-305847","article-title":"Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I\/II distinction of CD20 antibodies","volume":"118","author":"Niederfellner","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib51","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in\u00a0vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib52","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","article-title":"Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy","volume":"118","author":"Lim","year":"2011","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.heliyon.2019.e01297_bib53","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","article-title":"Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma","volume":"128","author":"Chiron","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.heliyon.2019.e01297_bib54","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.13132","article-title":"Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma","volume":"168","author":"Heinrich","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.heliyon.2019.e01297_bib55","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2012-01-404368","article-title":"Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients","volume":"119","author":"Salles","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.heliyon.2019.e01297_bib56","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.heliyon.2019.e01297_bib57","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib58","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib59","first-page":"196","article-title":"Radioimmunotherapy for B-cell non-hodgkin lymphomas","volume":"19","author":"Tomblyn","year":"2012","journal-title":"Cancer Contr."},{"issue":"31","key":"10.1016\/j.heliyon.2019.e01297_bib60","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib61","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3109\/10428194.2011.608445","article-title":"A phase I study evaluating ibritumomab tiuxetan (Zevalin(R)) in combination with bortezomib (Velcade(R)) in relapsed\/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma","volume":"53","author":"Beaven","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib62","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.beha.2012.04.004","article-title":"Radioimmunotherapy in mantle cell lymphoma","volume":"25","author":"Skarbnik","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"11","key":"10.1016\/j.heliyon.2019.e01297_bib63","first-page":"4483","article-title":"Immunophenotyping of leukemias using a cluster of differentiation antibody microarray","volume":"61","author":"Belov","year":"2001","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.heliyon.2019.e01297_bib64","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/sj.leu.2403822","article-title":"Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation","volume":"19","author":"Barrena","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.13099","article-title":"Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients","volume":"168","author":"Pagel","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib66","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2009-12-257485","article-title":"Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma","volume":"116","author":"Leshchenko","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.heliyon.2019.e01297_bib67","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ccr.2012.03.040","article-title":"Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals","volume":"21","author":"Lapalombella","year":"2012","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib68","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib69","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"issue":"18 Pt 2","key":"10.1016\/j.heliyon.2019.e01297_bib70","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/13543780903463854","article-title":"Milatuzumab \u2013 a promising new immunotherapeutic agent","volume":"19","author":"Berkova","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"12","key":"10.1016\/j.heliyon.2019.e01297_bib72","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2004-03-0890","article-title":"Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies","volume":"104","author":"Stein","year":"2004","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.heliyon.2019.e01297_bib73","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2010-08-303354","article-title":"Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in\u00a0vitro and in\u00a0vivo activity in mantle cell lymphoma","volume":"117","author":"Alinari","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.heliyon.2019.e01297_bib74","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1182\/blood-2011-06-363879","article-title":"FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death","volume":"118","author":"Alinari","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib75","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4161\/auto.19050","article-title":"FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?","volume":"8","author":"Alinari","year":"2012","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib76","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2015.04.008","article-title":"ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in\u00a0vitro and in\u00a0vivo","volume":"43","author":"Mani","year":"2015","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.heliyon.2019.e01297_bib77","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2019.e01297_bib78","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1182\/blood.V90.11.4297","article-title":"In\u00a0vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell energy but is insufficient to induce significant T-cell proliferation","volume":"90","author":"Dorfman","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.heliyon.2019.e01297_bib79","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone","volume":"91","author":"Dogan","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib80","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cyto.b.20631","article-title":"CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma","volume":"82","author":"Dakappagari","year":"2012","journal-title":"Cytom. B Clin. Cytom."},{"issue":"19","key":"10.1016\/j.heliyon.2019.e01297_bib81","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2005.09.018","article-title":"Phase I\/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma","volume":"23","author":"Czuczman","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.heliyon.2019.e01297_bib82","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells","volume":"194","author":"Klein","year":"2001","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2019.e01297_bib83","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib84","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI83535","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","author":"Yu","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2019.e01297_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/hon.948","article-title":"ROR1 expression is not a unique marker of CLL","volume":"29","author":"Barna","year":"2011","journal-title":"Hematol. Oncol."},{"issue":"37","key":"10.1016\/j.heliyon.2019.e01297_bib86","doi-asserted-by":"crossref","first-page":"24731","DOI":"10.18632\/oncotarget.25340","article-title":"Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma","volume":"9","author":"Yu","year":"2018","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib87","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.heliyon.2019.e01297_bib88","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib89","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00262-003-0496-2","article-title":"T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent","volume":"53","author":"Gruen","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"issue":"8","key":"10.1016\/j.heliyon.2019.e01297_bib91","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.molimm.2006.09.032","article-title":"CD19-\/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis","volume":"44","author":"Molhoj","year":"2007","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib92","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","article-title":"The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct","volume":"56","author":"Brandl","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"issue":"26","key":"10.1016\/j.heliyon.2019.e01297_bib93","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"issue":"5891","key":"10.1016\/j.heliyon.2019.e01297_bib94","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.heliyon.2019.e01297_bib95","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.heliyon.2019.e01297_bib96","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1182\/blood-2011-09-381988","article-title":"Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20\/CD74 bispecific antibodies in mantle cell and other lymphomas","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib97","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression","volume":"5","author":"Davis","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.heliyon.2019.e01297_bib98","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0609.2003.00007.x","article-title":"Loss of CD20 expression in relapsed lymphomas after rituximab therapy","volume":"70","author":"Haidar","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.heliyon.2019.e01297_bib99","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00277-003-0694-1","article-title":"CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature","volume":"82","author":"Alvaro-Naranjo","year":"2003","journal-title":"Ann. Hematol."},{"issue":"20","key":"10.1016\/j.heliyon.2019.e01297_bib100","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2019.e01297_bib101","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s12032-011-9955-3","article-title":"Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature","volume":"29","author":"Duman","year":"2012","journal-title":"Med. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2019.e01297_bib102","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.4049\/jimmunol.176.4.2600","article-title":"The shaving reaction: rituximab\/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes","volume":"176","author":"Beum","year":"2006","journal-title":"J. Immunol."},{"issue":"25","key":"10.1016\/j.heliyon.2019.e01297_bib103","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib104","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-06-2184","article-title":"Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy","volume":"67","author":"Jazirehi","year":"2007","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.heliyon.2019.e01297_bib105","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2003-06-2031","article-title":"Antibody specificity controls in\u00a0vivo effector mechanisms of anti-CD20 reagents","volume":"103","author":"Cragg","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib106","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2005.02720.x","article-title":"Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis","volume":"139","author":"Janas","year":"2005","journal-title":"Clin. Exp. Immunol."},{"issue":"25","key":"10.1016\/j.heliyon.2019.e01297_bib107","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib108","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2019.e01297_bib109","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.heliyon.2019.e01297_bib110","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2011-04-346411","article-title":"The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab","volume":"118","author":"Ahlgrimm","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.heliyon.2019.e01297_bib111","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1179\/joc.2007.19.3.315","article-title":"The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms","volume":"19","author":"Galimberti","year":"2007","journal-title":"J. Chemother."},{"issue":"11","key":"10.1016\/j.heliyon.2019.e01297_bib112","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844018376394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844018376394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:29:25Z","timestamp":1762511365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844018376394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2405844018376394"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e01297","relation":{},"ISSN":["2405-8440"],"issn-type":[{"type":"print","value":"2405-8440"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic antibodies for mantle cell lymphoma: A\u00a0brand-new era ahead","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2019.e01297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e01297"}}